CABG coronary bypass surgery
Conditions
Interventions
0.05 ml/kg dexamethason, i.v. (20 mg/ml, clear fluid) or placebo
Sponsors
Vrije Universiteit Medisch Centrum
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Patients undergoing coronary artery bypass surgery (CABG) Use of cardiopulmonary bypass (CPB) Age 18-75 years Informed consent
Exclusion criteria
Exclusion criteria: Re-operations Emergency operation Body surface area (BSA) 1.7 > BSA
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Expression of p38 in cultured cells and cardiac tissue | — |
Secondary
| Measure | Time frame |
|---|---|
| Pro-apoptotic signaling in atrial biopsies and cultured cells Blood will be sampled for the measurement of Tumor Necrosis Factor-alpha (TNF-*), IL-6, IL-8, IL-10 and IL-4 and CRP before induction of anesthesia and at the end of surgery. Plasma samples will be investigated for the presence of novel biomarkers: precursor peptides of ANP (proANP), vasopressin (Copeptin), Endothelin-1 (proET-1) and Adrenomedullin (proADM). Demographic variables: Age, gender, length, body weight, preoperative and postoperative hematocrit, hemoglobin, leukocyte count. Surgical characteristics: Surgery time, clamp time, CPB time | — |
Countries
Netherlands
Outcome results
None listed